Quick Answer
Nuvation Bio Inc. reported Total Revenue of $62.90 million for fiscal year 2025.
Nuvation Bio Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $62.90M +699.0% |
$7.87M | $0.00 | — | — | — |
| Revenue (ASC 606) | $62.90M +699.0% |
$7.87M | $0.00 | — | — | — |
| Net Income | -$204.63M +64.0% |
-$567.94M -649.2% |
-$75.80M +27.3% |
-$104.20M -20.0% |
-$86.85M -108.5% |
-$41.66M |
| Diluted EPS | -$0.60 +71.6% |
-$2.11 -502.9% |
-$0.35 +27.1% |
-$0.48 -9.1% |
-$0.44 | — |
| Total Assets | $594.82M +10.0% |
$540.63M -13.0% |
$621.48M -7.5% |
$672.14M -13.4% |
$776.15M +249.9% |
$221.79M |
| Cash and Equivalents | $164.09M +359.3% |
$35.72M -16.2% |
$42.65M -57.8% |
$101.10M -23.7% |
$132.42M | $0.00 |
| Stockholders Equity | $305.72M -34.1% |
$463.79M -23.4% |
$605.12M -7.6% |
$655.08M -12.2% |
$746.00M | $0.00 -100.0% |
| R&D Expense | $115.11M +16.1% |
$99.12M +39.0% |
$71.29M -18.8% |
$87.81M +27.2% |
$69.04M +111.8% |
$32.60M |
| Operating Income | -$213.06M +64.0% |
-$592.63M -493.7% |
-$99.82M +16.6% |
-$119.73M -28.3% |
-$93.32M -114.3% |
-$43.55M |
| Gross Profit | — | $795.0K | $0.00 | — | — | — |
| Shares Outstanding | 337.84M +0.0% |
337.84M +54.2% |
219.05M +0.2% |
218.63M +0.3% |
217.95M +46.2% |
149.04M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $13.12M | +1704.7% | +171.5% |
| Revenue (ASC 606) | September 30, 2025 | $13.12M | +1704.7% | +171.5% |
| Net Income | September 30, 2025 | -$55.79M | -35.4% | +5.4% |
| Diluted EPS | September 30, 2025 | -$0.16 | -6.7% | +5.9% |
| Total Assets | September 30, 2025 | $601.56M | +5.2% | -7.1% |
| Cash and Equivalents | September 30, 2025 | $98.90M | +229.3% | -60.1% |
| Stockholders Equity | September 30, 2025 | $325.88M | -35.2% | -12.6% |
| R&D Expense | September 30, 2025 | $28.85M | +4.0% | +5.4% |
| Operating Income | September 30, 2025 | -$56.43M | -17.3% | +11.3% |
| Gross Profit | September 30, 2025 | $9.77M | +1340.0% | +332.9% |
| Shares Outstanding | September 30, 2025 | 337.84M | +0.5% | +0.0% |
- Nuvation Bio Inc. reported Total Revenue of $62.90 million for fiscal year 2025.
- Nuvation Bio Inc. showed an increase of +699.0% in Total Revenue compared to the prior fiscal year.
- Nuvation Bio Inc. reported Revenue (ASC 606) of $62.90 million for fiscal year 2025.
- Nuvation Bio Inc. showed an increase of +699.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Nuvation Bio Inc. reported Net Income of -$204.63 million for fiscal year 2025.
- Nuvation Bio Inc. showed an increase of +64.0% in Net Income compared to the prior fiscal year.
- Nuvation Bio Inc. reported Diluted EPS of $0.60 per share (loss) for fiscal year 2025.
- Nuvation Bio Inc. showed an increase of +71.6% in Diluted EPS compared to the prior fiscal year.
- Nuvation Bio Inc. reported Total Assets of $594.82 million for fiscal year 2025.
- Nuvation Bio Inc. showed an increase of +10.0% in Total Assets compared to the prior fiscal year.
- Nuvation Bio Inc. reported Cash and Equivalents of $164.09 million for fiscal year 2025.
- Nuvation Bio Inc. showed an increase of +359.3% in Cash and Equivalents compared to the prior fiscal year.
- Nuvation Bio Inc. reported Stockholders Equity of $305.72 million for fiscal year 2025.
- Nuvation Bio Inc. showed a decrease of -34.1% in Stockholders Equity compared to the prior fiscal year.
- Nuvation Bio Inc. reported R&D Expense of $115.11 million for fiscal year 2025.
- Nuvation Bio Inc. showed an increase of +16.1% in R&D Expense compared to the prior fiscal year.
- Nuvation Bio Inc. reported Operating Income of -$213.06 million for fiscal year 2025.
- Nuvation Bio Inc. showed an increase of +64.0% in Operating Income compared to the prior fiscal year.
- Nuvation Bio Inc. reported Gross Profit of $795.0 thousand for fiscal year 2024.
- Nuvation Bio Inc. reported Shares Outstanding of 337.84 million shares for fiscal year 2025.
- Nuvation Bio Inc. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: